Synbio Pharmaceutical---Clinical trial targeting CMV infection after hematopoietic stem cell transplantation in ATHENA trial begins

Synbio Pharmaceuticals ＜4582＞ announced on the 8th that it has begun clinical trials targeting cytomegalovirus infection (CMV infection) after hematopoietic stem cell transplantation in a phase 2a clinical trial (ATHENA test) with the injectable brincidofovir. The company plans to complete the injectable brincidofovir phase 2a clinical trial targeting adenovirus infection (AdV infection) after hematopoietic stem cell transplantation in the first half of the 2024/12 fiscal year. This is the second indication

Fisco JapanMay 8 21:02 ET

GMOTECH, GMOTECH, etc.

＜3628＞Data HR revised downward, sales forecast for the current fiscal year 4.90 billion yen ← 6.300 billion yen ＜4579＞LaQuoria Drug Discovery Phase I Clinical Trials Begin in Australia ＜4582＞Clinical Trials Targeting Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation in Phase IIa Clinical Trial (ATHENA Test) with the Synbio Pharmaceutical Injection Brincidofovir Begin Clinical Trials Targeting Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation ＜6026＞GMOTECH Upward Revised for the Current Fiscal Year ＜6026＞GMOTECH Upward Revised for the Current Fiscal Year Forecast 1,040 million yen ←

Fisco JapanMay 8 18:30 ET

SymBio Pharmaceuticals: Confirmation

Futu NewsMay 8 02:29 ET · Announcements

SymBio Pharmaceuticals: Quarterly Report - 20th Quarter 1 (2024/01/01 - 2024/03/31)

Futu NewsMay 8 02:29 ET · Announcements

Synbio Pharmaceuticals--Continued promotion of research and development activities despite 1Q sales decline

Synbio Pharmaceuticals ＜4582＞ announced consolidated financial results for the 1st quarter (January to March 24) of the fiscal year ending 2024/12 on the 7th. Net sales decreased 61.3% from the same period last year to 597 million yen, operating loss was 806 million yen (profit of 51 million yen in the same period last year), ordinary loss was 727 million yen (profit of 0.48 billion yen), and quarterly net loss attributable to parent company shareholders was 777 million yen (same profit of 0.4 billion yen). Currently, treaxine (R) intravenous infusion solution 100 mg/4 mL [RTD (Rea)

Fisco JapanMay 7 20:49 ET

Medlec, Note, etc. [Emerging Markets Press Release]

＜3645＞Medical Net Shareholder Benefit System＜4586＞Medlec 28th Stock Acquisition Rights (with exercise price amendment clause) number of shares issued from the 7th, 875,000 shares ＜4582＞ Symbio Pharma downward revisions, operating loss forecast for the current fiscal year △ 3.702 billion yen ← △ 2,837 billion yen ＜4978＞Reprocel downward revision, previous fiscal year operating loss forecast △ 409 million yen ←△ 110 million yen ＜5243＞net subsidiary established and new business started < 7372 > below décolletage HD

Fisco JapanMay 7 18:00 ET